Publication details
Pokroky v léčbě srdečního selhání se sníženou ejekční frakcí
| Title in English | Advances in the treatment of heart failure with reduced ejection fraction |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| web | https://farmakoterapeutickarevue.cz/cs/pokroky-v-lecbe-srdecniho-selhani-se-snizenou-ejekcni-frakci |
| Keywords | heart failure with reduced ejection fraction; HFrEF; pharmacotherapy |
| Description | Pharmacotherapy of patients with heart failure with reduced ejection fraction (HFrEF) is a very dynamic branch of cardiology with intensive research. The European Society of Cardiology (ESC) guidelines from 2021 were significantly updated in the 2023 supplement. Current mainstays of HFrEF treatment include angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI), beta-blockers, sodium-glucose cotransporter-2 inhibitors (SGLT2) (gliflozins) and mineralocorticoid receptor antagonist (MRA). Diuretics are recommended for patients with congestion. There are also other medicaments that have already gained their place in the treatment strategy. These are mainly intravenous iron preparations, vericiguat and tafamidis. Proper management of HFrEF treatment is including prevention, early initiation of treatment and proper dose uptitration. |